KRT88P and fibrosis: For those with low risk of HBVr, including HbsAg-positive and HbsAg-negative but anti-HBc-positive patients, initiation of pre-emptive nucleos(t)ide analogues (NUCs) was based on whether the patients had advanced fibrosis or cirrhosis.